Unilever invests €35 million in AI-led Indian R&D hubs

By Sophie Lindqvist

Unilever will invest €35 million to transform its R&D centres in Mumbai and Bangalore into “next-generation” hubs focused on artificial intelligence and bioscience-led innovation. The consumer-goods company and Dove owner made the commitment as part of a broader effort to connect scientific work with product development at greater speed and scale.

Unilever has already invested €20 million in the two centres over the past five years. The company says the expansion will support science, automation, predictive modelling and rapid prototyping.

Richard Slater, Chief Research & Development Officer at Unilever, said: “India already plays a central role in Unilever’s global innovation network, and this investment will further strengthen its position as one of our largest R&D hubs.”

That is the strategic claim.

From insight to scale-up

The Mumbai site will develop further into a product innovation centre, combining several functions in one integrated environment:

• Consumer insights and new measurement approaches.
• Product and format science, plus packaging design.
• Rapid prototyping and scale-up capabilities.

The centre will also facilitate collaborations with academics, technology companies and innovators. Unilever says the integrated model targets a faster route from exploring possibilities through to scaling innovations.

Five years of biological ambition

Of the €35 million, €5 million will go toward establishing a strategic Bio-Futures Partnership in Bangalore. Its five-year aim is to accelerate innovation across human biology, microbiome science, biotechnology and biomanufacturing.

At both locations, scientists and product developers will receive support from AI, automated experimentation, predictive modelling and digital twins. Unilever says these tools can speed the path from exploring possibilities through to scaling innovations.

The programme is intended to shape innovation across Unilever’s beauty, wellbeing, personal care and home care divisions globally. It follows the opening of the company’s fragrance hub in India earlier this year.

Slater also pointed to the depth of scientific expertise and knowledge Unilever has built in India over decades, together with talent across a wide range of disciplines. He framed the market rationale:

“India is also one of our most important growth markets. It is changing fast. Consumer expectations are rising, needs are evolving and the pace of innovation keeps on accelerating. That makes it an incredibly important place for us to learn, create and scale new ideas.”

What does this change for dermatology teams?

Not much yet. The announcement reports no patient cohort, clinical endpoint, skin-specific formulation, device parameter or regulatory submission. It describes an R&D system, not a clinical study.

The investment changes upstream product development, not care delivery. No diagnostic criterion, treatment recommendation or prescribing decision changes because of it. For clinicians and formulators, the useful distinction is clear: AI, automated experimentation, predictive modelling and digital twins are development tools, not evidence of efficacy.

Among the areas with potential relevance to dermatology, microbiome science appears in the Bangalore remit. The announcement identifies no target organism, assay, candidate product or skin indication. Teams assessing future beauty and personal-care products should therefore ask for ingredient-level data and condition-specific testing rather than treating the investment itself as proof of benefit.

Until that evidence exists, the defensible conclusion is narrow: Unilever is funding R&D infrastructure and capability. The next milestone is whether the expanded hubs can turn AI, bioscience and rapid prototyping into products Unilever can scale globally, with any skin-specific claims supported by evidence generated after this investment.